富马酸替诺福韦二吡呋酯对血脂影响的研究进展  

Research progress on the effect of tenofovir disoproxil fumarate on blood lipid profile

作　　者：段袁琴 胡鹏[1] Duan Yuanqin;Hu Peng(Department of Infectious Diseases,Institute for Viral Hepatitis,the Key Laboratory of Molecular Biology for Infectious Diseases,Chinese Ministry of Education,the Second Affiliated Hospital of Chongqing Medical University,Chongqing 400010,China)

机构地区：[1]重庆医科大学附属第二医院感染科,教育部感染性疾病分子生物学重点实验室,重庆医科大学病毒性肝炎研究所,重庆400010

出　　处：《中华肝脏病杂志》2023年第10期1103-1107,共5页Chinese Journal of Hepatology

摘　　要：富马酸替诺福韦二吡呋酯(TDF)是一种新型核苷酸类逆转录酶抑制剂,主要用于治疗人类免疫缺陷病毒和乙型肝炎病毒感染。近年来越来越多的研究发现,TDF治疗可以降低艾滋病和慢性乙型肝炎患者的血脂,而血脂又和疾病进展以及心血管事件的发生息息相关。现就TDF对血脂影响的研究进展作一综述,旨在为TDF的合理用药提供依据。Tenofovir disoproxil fumarate(TDF)is a novel nucleotide reverse transcriptase inhibitor that is mainly used to treat human immunodeficiency virus(HIV)and hepatitis B virus(HBV)infections.In recent years,an increasing number of studies have demonstrated that TDF treatment can reduce blood lipid levels in patients with AIDS and chronic hepatitis B and has a close correlation with the severity of the disease and the occurrence of cardiovascular events.This article reviews the research progress on the effect of TDF on blood lipid profiles,with the aim of providing a basis for rational use of TDF.

关 键 词：乙型肝炎病毒 血脂 人类免疫缺陷病毒 富马酸替诺福韦二吡呋酯 

分 类 号：R512.62[医药卫生—内科学]